Replies to post #309183 on Avid Bioservices Inc (CDMO)

[biopharm]

Dr Jedd Wolchok Jan 2018 appearance wonder if there are nondisclosures for this conference, as I still see Tesaro has nondisclosures in IO pipeline (very possible tied to PS Targeting)

_______


T Cell Dysfunction, Cancer and Infection (A3)

Scientific Organizers: Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok

January 16—20, 2018
Beaver Run Resort, Breckenridge, Colorado, USA

Sponsored by Incyte Corporation, Juno Therapeutics and TESARO, Inc.

...
...

Philip D. Greenberg, University of Washington, USA
Novel Approaches to Isolating Receptors and Engineering Cells to Target Tumor Antigens

...
...

Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center, USA
Clinical Results of Combined Checkpoint Blockades
...

https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1545

_________


https://www.linkedin.com/in/lena-evilevitch-phd-4a92a68

Anyhow....Peregrine ex Medical Director Vladimir has a relative that is also Medical Director over at Tesaro

Tesaro BOD:

BOARD OF DIRECTORS
Our Board is driven by sound corporate governance.

David Mott
General Partner, New Enterprise Associates

Lawrence Alleva
Retired Partner, PriceWaterhouseCoopers

James Armitage, M.D.
Joe Shapiro Chair for the Study of Oncology and Clinical Research, University of Nebraska Medical Center

Earl (Duke) Collier, Jr.
President, The Braxton Company

Mary Lynne Hedley, Ph.D.
President, Chief Operating Officer and Co-Founder, TESARO

Lonnie Moulder
Chief Executive Officer and Co-Founder, TESARO

Garry Nicholson
President and CEO, XTuit Pharmaceuticals

Arnold Oronsky, Ph.D.
General Partner, InterWest Partners

Kavita Patel, M.D., M.S., F.A.C.P.
Senior Fellow, The Brookings Institution

Beth Seidenberg, M.D.
Partner, Kleiner Perkins Caufield & Byers



SENIOR LEADERSHIP
Our leadership team has extensive experience in developing, obtaining regulatory approvals for and successfully commercializing a variety of oncology products. In total, they have decades of combined experience spanning a range of cancers and other diseases.


Lonnie Moulder
Chief Executive Officer


Mary Lynne Hedley, Ph.D.
President, Chief Operating Officer


Stephen Andre
Senior Vice President, Human Resources


Grant Bogle
Senior Vice President, Chief Commercial Officer


Allene Diaz
Senior Vice President, Global Commercial Development


Joseph Farmer
Senior Vice President, General Counsel and Corporate Secretary


Jeffrey Hanke, Ph.D.
Executive Vice President, Research and Development, and Chief Scientific Officer


Martin Huber, M.D.
Senior Vice President, Chief Medical Officer


Jennifer Jackson, Ph.D.
Senior Vice President, Global Regulatory Affairs & Quality Assurance


Orlando Oliveira
Senior Vice President and General Manager, International


Timothy Pearson
Executive Vice President, Chief Financial Officer

[biopharm]

Why has Ronin Hedge Group not filed yet with SEC to amend their filings and remove ANY and ALL statements for wanting to shut down Peregrine R&D re: PS Targeting...

Hell, NO mention of their experts and have they not just seen the upfront abstract info for this weekend at SITC 2017 where the Bavituximab arm of patients that went on with FDA SOC have not met MOS yet!!!! Vs the Docetaxel arm have reached MOS

What do they not understand ? PS Targeting trying to be handcuffed by a Ronin Hedge Group BOD where it then can be transferred like Medarex for Breadcrumbs ??? No way.....let's go Ronin ....speak and file with SEC that R&D is here to stay ...with NCCN, MSK and Dr Jedd Wolchok and ALL other undisclosed collaborations

Biomarkers being minted as we speak and could be the goldmine all BPs require for fast FDA approvals and may not even need large clinical trials the way we knew it....

The Enlightenment Age of Disease.....is here now and others will require PS Targeting as well. Beth Seidenberg has had some interesting words lately, that Big Pharma is the last segment for paradigm shifts that have not shaken up the industry YET

Speaking of Tesaro, Tesaro, Incyte and Juno sponsoring this Jan 2018 conference....that Peregrine collaborator MSKs Dr Jedd Wolchok (scientific organizer at event) will be presenting .....(wonder which combos he will discuss and this is exactly why Ronin group must not halt PS Targeting with Dr Wolchok or MSK or NCCN or others....

ASK Stephen White / Ronin group to not halt PS Targeting activity because it is possible that any unfinished data that is maturing may not reach publication or symposiums such as below in 5 months. Why the hell does Ronin group not file with SEC to legally back up what Peregrine investors want?? Any collaborations with Dr Jedd Wolchok ...MSK .NCCN etc must stay active or does Ronin group have an agenda to cancel these collaborations ???
..

.

[biopharm]

Dr Jedd Wolchok closing in on this Jan 2018 presentation .....and who knows, but Amgen, Regeneron and Surface were added sponsors and how will some BPs open up their overseas $$$$ to Peregrine Pharmaceuticals by the end of this conference ?

T cell Dysfunction, Cancer and Infection (A3)

Scientific Organizers: Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok

January 16—20, 2018
Beaver Run Resort, Breckenridge, Colorado, USA

Sponsored by Amgen Inc., Incyte Corporation, Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Surface Oncology and TESARO, Inc.